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1. INTRODUCTION 
1.1. NITRIC OXIDE and NITRIC OXIDE SYNTHASES 
Nitric oxide (NO) is a fairly stable and highly diffusible gas signalling molecule with a 
crucial role in animal pathophysiology [Wink and Mitchell, 1998]. In eukaryotic cells NO 
is mostly synthesized by a family of enzymes called NO synthases (NOSs). Three different 
isoforms of NOS are expressed in mammals and differ in their functions. The neuronal 
NOS (nNOS or NOS1) and endothelial NOS (eNOS or NOS3), named after the tissue in 
which they were first identified, are expressed constitutively, but can be also acutely 
activated by protein kinases or calcium. Under normal metabolic conditions NOSs usually 
generate NO for signalling purposes. In the nervous system NO is known to promote 
signal transmission between neurons, whereas at the level of endothelial cells, it regulates 
the vascular tone by inhibiting smooth cells contraction and platelet aggregation. The 
inducible NOS (iNOS or NOS2), releases large amount of NO and for longer period than 
the other NOSs in response to proinflammatory or inflammatory mediators (e.g. 
cytokines). NO produced by iNOS represents an important defence mechanism against 
pathogens in the innate immune responses [Liew and Cox, 1991]. Signals able to trigger 
the NOS2 expression leading to inflammatory cascade activation can be for example 
bacterial lipopolysaccharide or cytokines.  
NOS enzymes are able to produce NO by catalysing the oxidation of L-arginine to L-
citrulline through a two successive mono-oxygenation reactions (Fig. 1) [Alderton et al., 
2001]; the NOS exists as a homodimer. Each monomer can be structurally and functionally 
divided in two main domains: a C-terminal reductase domain and an N-terminal oxygenase 
domain. The C-terminal domain contains the binding site for one of each molecule: 
NADPH, FMN and FAD; whereas the N-terminal binds haem and tetrahydrobiopterin as 
cofactors as well as L-arginine. To become active each enzyme must assemble into 
dimmers, which are specifically designed to enable electron transfer from the reductase 
domain of one monomer to the oxygenase domain of the other. 
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Figure 1. Scheme of NO synthesis [from University of Reading website] 
 
Notably NO is involved in several processes, such as blood vessel dilation, regulation 
of the immune function, neurotransmission in the brain and in the peripheral nervous 
system and modulation of mitochondrial respiration. It can work, depending on its 
intracellular concentration and localization, as a physiological signalling molecule or as a 
toxic agent for both parasitic and human cells [Poole, 2005].  
NO exerts its signalling functions either by binding to the haeme iron of guanylyl 
cyclase (GC), triggering GC activation, cyclic GMP production and leading to consequent 
downstream target modifications [Michell et al., 2001], or through post-translational 
protein modifications. This latter event occurs usually for S-nitrosation of cysteine residues 
or nitration of tyrosine groups. The control of cell survival is strictly dependent on NO 
concentration: at low doses it inhibits programmed cell death; at higher doses instead, it is 
lethal. The threshold at which NO can act as a pro apoptotic molecule varies considerably 
with the cell type. The anti-apoptotic pathways are mainly regulated by NO caspases 
inactivation due to S-nitrosation; the apoptotic events are instead linked to p53, a well-
established tumour suppressor and transcriptional activator [Messmer et al., 1994].   
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NO has a crucial role in cytotoxic events (Fig. 2) due to its radical nature. NO is a 
molecule able to react with various cell constituents as molecular oxygen (O2), superoxide 
(O2
-), transition metals in a free or complexes form and nucleophilic centres in proteins 
[Stroes et al., 1998]. Superoxide for example can itself combine with nitric oxide 
generating peroxynitrite anion (ONOO-), a harmful molecule with high oxidant power able 
to diffuse through cells damaging proteins, lipids and DNA bases [Szabo and Ohshima, 
1997]. These reactions are very useful in protecting our organism from parasites but their 
persistence may result fatal for cell survival. Therefore, in order to cope with oxidative and 
nitrosative stress and keep the level of reactive chemical species within a physiological not 
harmful range, the human organism has developed an efficient antioxidant system. (Fig. 3) 
[Krauss, 2003]. 
 
 
Figure 2. Roles of NO in mammalians [from Grisham M. B. et al. 1999] 
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Figure 3. Human antioxidant system  
 
From the pharmacological point of view, NO has been demonstrated as an important 
agent for treatment of several disease conditions [Wink and Mitchell, 1998]. According to 
this beneficial property, various prodrugs able to release NO at specific site have been 
developed. Due to its free radical nature NO is a very reactive molecule with a rapid rate 
of diffusion in biosystems and also a fairly short half-life [Archer, 1993] that depends on 
cell environment or medium composition. One of the main challenges for researchers has 
been to find out the optimal rate of NO release from NO donors or persistence into 
bioenvironments for a number of specific conditions [Ignarro et al., 2002]. 
After the discovery that several mechanisms involved in the maintenance of blood 
pressure in vivo (e.g. smooth muscle relaxation) use NO as an intermediary, this molecule 
became an interesting potential agent in the treatment of cardiovascular diseases, diffused 
worldwide [Naseem, 2005]. Taking advantage of the NO ability to induce relaxation of the 
smooth muscle cells of blood vessels (Fig. 4), several pharmacological NO-releasing 
compounds have been developed with a prolonged half-life (several hours) and a reduced 
incidence of drug tolerance compared to conventional NO donors as for example 
nitroglycerin, a drug widely used for decades in the treatment of angina pectoris [Murray et 
al., 2003].  
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Figure 4. Synthesis of NO in endothelium and signal transmission in smooth muscle [from 
annals.org website] 
 
1.2. MITOCHONDRIA 
Mitochondria are the eukaryotic cell organelles responsible for the most of useful 
energy derived from carbon sources and converted to adenosine triphosphate (ATP) during 
the oxidative phosphorylation [Karp, 2010]. According to the endosymbiotic theory, 
mitochondria represent formerly free-living aerobic bacteria taken inside by primeval 
anaerobic eukaryotes around 1.5 billion years ago [Martin and Muller, 1998]. The 
mitochondria structure may validate this theory since they have a double membrane 
system: a smooth outer membrane and a noticeably folded inner membrane that enclose the 
mitochondrion matrix (Fig. 5) [Alberts et al. 2002]. Like its bacterial ancestor, the 
mitochondrial inner membrane has a structure very similar to prokaryotes containing, 
instead of cholesterol, cardiolipin- a typical component of prokaryotic membranes [Frey 
and Mannella, 2001]. 
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The folds of inner membrane are called cristae; they increase the mitochondrial surface 
and contain five enzymatic complexes forming the oxidative phosphorylation system 
[Perkins et al., 1997]. Another proof for bacterial origin of mitochondria is the presence of 
their own DNA that is separated from the nuclear genome and encodes for 13 proteins 
involved in the electron transfer and oxidative phosphorylation, 2 ribosomal RNA (rRNAs) 
and 22 transfer RNAs  (tRNAs) [Kurland and Andersson, 2000].  
Mitochondrial DNA (mtDNA) is a maternally inherited circular molecule of 16,569 
nucleotides. It is a multi copy genome whose number of molecules depends on tissue 
activity and energy demand [Mehrabian et al., 2005]. As nuclear DNA (nDNA), mtDNA is 
susceptible to point mutations but, due to its features, the results are more deleterious than 
in the nuclear DNA. Being located next to the oxidative phosphorylation machinery, where 
formation of reactive oxygen species can occur, the mitochondrial genome is more 
exposed to oxidative stress [Doudican et al., 2005]. Moreover it lacks protective histones 
and has a simple DNA repairing system [Wei, 2014]. Taken all together, these 
characteristics lead to a higher susceptibility of mtDNA to oxidative stress, brakes and 
point mutations. 
 
 
Figure 5. Mitochondria structure scheme and microscopic photography [from 
thescienceupdate.blogspot.it website]  
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1.2.1. Oxidative phosphorylation 
Oxidative phosphorylation (OXPHOS) is one of the most important functions of 
mitochondria made possible due to specific mitochondrial membrane features. The 
mitochondrial outer membrane is porous whereas the inner membrane acts as a barrier to 
the movement of many biological metabolites [Mathews et al., 2000]. Carefully selected 
metabolites are transported across the inner membrane with the assistance of proteins that 
are placed on it in a large number [Berg et al., 2000]. 
Oxidative phosphorylation is the main pathway to obtain energy (ATP) in mammalians 
cells. In fact, carbohydrates, fats and proteins are oxidized firstly in the cell cytosol and 
then in the mitochondrial matrix in a process known as Krebs cycle (Fig. 6). During these 
processes, NAD+ and FAD2+ are reduced and their reduced equivalents, NADH and 
FADH2, are accumulated within the cell [Murray et al., 2003]. 
 
 
Figure 6. Degradation of triglycerides and glucose and synthesis of NADH and FADH2 
[from aziendanatura.it website]  
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During oxidative phosphorylation, electrons from reduced NADH and FADH2 are 
transferred along the redox carriers constituting the respiratory chain located in the inner 
mitochondrial membrane. These are four multi-subunits protein complexes (I, II, III and 
IV) and two smaller carriers (coenzyme Q and cytochrome c). Complex I accepts electrons 
from the NADH while Complex II is an entry point for electrons from the FADH2. Carried 
by coenzyme Q and subsequently by Complex III and cytochrome c, electrons flow 
through the Complex IV and are donated to the oxygen molecule forming water using H+. 
At the level of complexes I, III and IV, the free energy (G) released by the redox reaction 
accounting for electrons transfer, is used to translocate protons (H+) from the 
mitochondrial matrix into the intermembrane space. This vectorial accumulation of protons 
generates both a chemical and an electrical potential gradient across the inner membrane, 
which is used as a proton-motive force to drive ATP synthesis, the so-called µH+ 
[according to Michell et al. 2001]. This is done in the presence of Pi and ADP by a special 
multisubunit enzyme also located on the inner membrane and called ATP synthase (F0F1 
ATPase or complex V). One of its subunits, F0, allows the flow of protons down the 
gradient. The proton-motive force allows rotational catalysis and consequently binding 
ADP and inorganic phosphate into ATP with the assistance of a subunit called F1 [Murray 
et al., 2003]. The exchange of ATP with ADP from inside of the mitochondrion to outside 
is catalyzed by the ATP/ADP translocase [Gilbert, 2000]. 
Oxidation of every FADH2 leads to synthesis of 2 ATP whereas 3 ATP molecules are 
formed upon oxidising one NADH [Mathews et al., 2000]. Each respiratory complex 
includes a number of different coenzymes, such as flavins (FMN or FAD in complexes I 
and II), iron-sulphur clusters (in I, II and III) and haem groups (in II, III and IV) [Berg et 
al., 2000]. 
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Figure 7. Electron transport and oxidative phosphorylation systems [from 
cicres.ahajournals.org website] 
  
Mitochondrial respiration is the main and the most efficient way used by the cell to 
obtain the energy but on the other side, it is the source of reactive oxygen species that can 
react with NO (see Fig. 7). These reactive oxygen and nitrogen species (RONS) can be 
eliminated enzymatically (e.g. by glutathione peroxidase or manganese superoxide 
dismutase) and/or non-enzymatically (cytochrome c, ascorbic acid or vitamin E) [Nickel et 
al., 2014]. NO is known to control mitochondrial respiration by inhibiting many OXPHOS 
components, always and primarily complex IV but also complex I, depending on 
experimental conditions. Prolonged inhibition of OXPHOS following the overproduction 
of RONS leads to ATP deficiency and consequently to cell death via apoptosis or necrosis.  
Reaction with complex IV occurs at nanomolar NO concentration, is quick and 
reversible, while inhibition of complex I occurs after a long exposure to much higher 
concentration of NO (millimolar).  Inhibition of complex IV (cytochrome oxidase) takes 
place at the binuclear haem a3-CuB active site and the occurrence of the inhibition strongly 
depends on the electron flux through the respiratory chain as well as the relative 
concentrations of O2 and NO [Sarti et al., 2000 and Vicente, 2014]. 
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Complex I, also called NADH-coenzyme Q reductase, is the entry point for electrons 
into the respiratory chain and it is consisted of 46 separate polypeptide chains. As 
prosthetic groups, there are tightly bound FMN-containing flavoprotein and at least six 
iron-sulphur centres, which undergo cyclic oxidoreduction between ferrous and ferric state 
(Fig. 8) [Mathews et al., 2000]. Complex I is considered one of the major cellular ROS 
sources, produced principally at the coenzyme Q-binding and the flavin mononucleotide 
sites [Lin et al., 2012]. NO inhibits complex I via S-nitrosation of Cys39 exposed on ND3 
surface. This reaction depends on the structural conformation of the complex, which is 
conditioned by the availability of O2 and mitochondrial NADH [Sarti et al., 2012]. 
Moreover, this S-nitrosation regulates different functions, like control of ROS generation 
and cytoprotection after I/R (ischemia and suddenly reperfusion condition) [Sarti et al., 
2012]. 
  
 
Figure 8. Complex I structure and function in electron transport system [from biochemj.org 
website]  
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1.3. MITOCHONDRIAL DISEASES 
Mitochondrial diseases are disorders caused by mutations in the mtDNA or nDNA 
genes encoding for proteins involved in the mitochondrial respiratory chain function 
[McFarland et al., 2010]. These disorders have a worldwide prevalence estimated around 
1:8500 [Arpa et al., 2003] and at moment they lack efficient therapies. These disorders are 
clinically heterogeneous; most of them affect both muscles and brain (mitochondrial 
encephalomyopathies), since the activity of these systems is highly dependent on the ATP 
availability (Fig. 9) [Mann et al., 1992]. Common diseases, such as Alzheimer’s and 
Parkinson’s disease, may be also correlated with variations of mitochondrial genome 
[Taylor and Turnbull, 2005]. As mentioned above (chapter1.2), 13 mitochondrial proteins 
are encoded by the mitochondrial genome and more than 70 mitochondrial proteins are 
encoded by the nuclear genome, synthesized in cytoplasm and subsequently imported 
inside the organelles [Anderson et al., 1981]. Complex II, coenzyme Q and cytochrome c 
are completely encoded by nDNA while mtDNA encodes for seven subunits of complex I 
(ND1-ND4, ND4L, ND5 and ND6), one of complex III (cytochrome b), three of complex 
IV (COXI-COXIII) and two of complex V (ATPase6 and ATPase8) [Carelli et al., 2004]. 
 
 
 
 12 
 
 
Figure 9. Organs and systems more sensitive to mitochondrial dysfunctions [from 
accessmedicine.com website] 
 
The number of mitochondria in each cell is highly variable (from few hundreds to 
thousands) and depends on cell activity and metabolism; in those tissues with a high 
metabolic activity (e.g. brain, heart and skeletal muscle) it can reach 2000 copy per cell 
[Alberts et al., 2002]. In normal cells all mtDNA molecules are identical, a situation known 
as “homoplasmy”; on the contrary when a deleterious mutation is present it can affect just 
a portion of mtDNA in a condition called “heteroplasmy” (Fig. 10) [Wallace and Chalkia, 
2013]. It is therefore clear that the relative proportion of non-mutated and mutated mtDNA 
is responsible for causing a mitochondrial disease that occurs when a certain amount of 
wild-type mtDNA is insufficient to compensate for the mutant mtDNA in a specific organ 
and tissue of the individual [DiMauro and Davidzon, 2005].  
 13 
 
 
Figure 10. Possible proportions of wild type and mutated mitochondrial DNA 
 
As already mentioned, mitochondrial disorders can be related to mtDNA point 
mutations or nuclear DNA protein-coding genes defects (Fig. 11). The first category 
includes syndromes like Leber’s hereditary optic neuropathy (LHON), the most common 
mitochondrial disorder caused by specific mtDNA point mutations affecting complex I 
subunit genes; lactic acidosis and stroke-like episodes (MELAS), a disorder commonly 
associated with a mutation in position 3243A>G of the tRNALeu(UUR) gene [Goto et al., 
1990]; myoclonus epilepsy with ragged red fibbers (MERRF, caused by the A8344G 
mutation in the tRNALys gene of mtDNA) [Shoffner et al., 1990]; ataxia and retinitis 
pigmentosa (NARP) and maternally inherited Leigh syndrome (MILS), two clinically 
different disorders both associated to a mutation on the gene encoding for ATPase6 subunit 
[Di Mauro and Bonilla, 2004]. The group of disorders caused by defects in the nuclear 
DNA encoding for mitochondrial protein includes autosomal dominant optic atrophy 
(ADOA) and Friedreich’s ataxia (FRDA). 
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Figure 11.  Mitochondrial genome coding subunits of the OXPHOS complexes and 
diseases arising from the specific mutations. Mutations impairing mitochondrial protein 
synthesis are shown in blue while mutations resulting in protein coding genes are shown in 
red [from clinicalgate.com website] 
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1.3.1. Leber’s Hereditary Optic Neuropathy 
LHON is a rare mitochondrial disease affecting usually young men in their early 
adulthood. It was described for the first time by the German ophthalmologist Theodor 
Leber in 1871. He was observing four families with young men members that were 
suffering from abrupt loss of vision in both eyes, either simultaneously or sequentially 
[Wallace, 1986]. 
LHON disorder is a central nervous system disease caused by single point mutations of 
those mtDNA genes encoding for Complex I subunits (Fig. 12). Several mutations were 
described but the most common ones (90-95%) are: G11778A in ND4, G3460A in ND1 
and T14484C in ND6 [DiMauro and Davidzon, 2004]. LHON pathology is characterized 
by a dysfunction of the optic nerves leading to bilateral loss of vision due to retinal 
ganglion cells (RGCs) death [Lehninger et al., 2005], but can be accompanied by other 
neurological disorders. Some neuropathological studies of LHON show lesions in both 
white matter and in the optic nerve showing demyelization, vacuolisation, cystic necrosis, 
plaques and occasionally inflammatory cell infiltrates [Kovács, et al. 2004]. Moreover, 
several studies showed that LHON cell death is apoptotic [Battisti et al., 2004]  
It is not clear yet why these mutations cause disorders primarily only in the RGCs and 
optic nerve even though they are widespread all around the body [Lin et al., 2012]. From 
the biochemical point of view mutated mitochondria are less effective in energy producing 
because of Complex I mutations. The cells attempt to gain energy both enhancing Complex 
II activity and compensating the OXPHOS failure overusing the glycolytic pathway. These 
strategies are not sufficient to supply the required ATP and the OXPHOS dysfunction 
leads to a chronic oxidative stress levels increase [Lehninger et al., 2005]. Studies 
performed on a LHON mouse model revealed that even though the mutated cells are able 
to maintain basal ATP levels, their viability is deeply damaged by the oxidative stress 
resulting from Complex I alteration [Lin et al., 2012].  In particular, it was demonstrated 
that under physiological conditions the antioxidant cells defence system is sufficient to 
balance the subtle mitochondrial dysfunction, but in presence of an increased metabolic 
demand, ROS production sensibly increases leading to cell damage and triggering the 
apoptotic pathway [Carelli et al. 2004]. 
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Figure 12. A schematic section through the human eye with a schematic enlargement of the 
retina [from webvision.med.utah.edu website] 
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2.  AIM OF THE PROJECT 
The first clinical description of a young man patient suffering from LHON was reported 
in the 1871, but only in the 1998 Wallace and colleagues discovered the first LHON-
associated mutation in ND4 gene of mitochondrial DNA (mtDNA) coding for a subunit of 
mitochondrial Complex I. Since then, other mutations have been reported to be associated 
with LHON disorder and different pathogenic hypothesis have been proposed. Although 
several studies unravelled the main LHON features, several open questions about the 
pathophysiology of this disease still persist, making difficult the development of an 
efficient therapeutic approach.  
As mentioned above, LHON is a disorder caused by mtDNA point mutations in the 
genes coding for the OXPHOS Complex I subunits. From the biochemical point of view 
the bioenergetics failure and the enhanced reactive oxygen species (ROS) production are 
the typical hallmarks of LHON disease, unable, however, to explain the late onset and the 
incomplete penetrance. It seems that the presence of the mutation is necessary but not 
sufficient to trigger the disease and other factors could be involved. Since LHON is 
characterized by a deficit in the oxidative phosphorylation chain and NO· is an important 
signalling molecule exerting several pathophysiological actions in mammals, in particular 
is an established modulator of mitochondrial function, we have been wondering if it might 
have a role in the LHON development and progression.  
The aim of this thesis work was to unravel the potential role of NO· thus of the 
nitrosative stress, in the LHON pathophysiology. In order to address this issue we have set 
the protocols to measure the mRNA level of NOSs of LHON cells, and to test their 
viability when cultured in presence of the NO· releaser DETA-NONOate. 
 
 18 
 
3. MATERIALS AND METHODS 
3.1. CELL CULTURES 
3.1.1. Cell lines 
The Leber’s hereditary optic neuropathy (LHON) cell line was obtained from a female 
patient affected by A11778G LHON mutation. Healthy individuals of same sex and age 
were chosen as controls. Lymphoblast cell lines were established by Epstein - Barr virus 
(EBV) transformation of leukocytes isolated from the whole blood. All EBV-transformed 
cell lines were maintained in prescribed medium (RPMI 1640) supplemented with 20% 
heat inactivated fetal bovine serum (FBS), 2 mM L-glutamine, non-essential amino acids 
(100 units/mL penicillin and 100 mg/mL streptomycin) (Table 1) and grown in T25 cm2 
tissue culture flasks under standard conditions [5% CO2, 95% relative humidity and 37°C]. 
RPMI-1640 is a medium developed for the long-term culture of peripheral blood 
lymphocytes and is able to support the growth of a wide variety of cells in suspension as 
well as a number of cells grown as monolayers. RPMI 1640 medium contains sodium 
bicarbonate commonly used as a buffering component to guarantee the optimal pH range 
of 7.2-7.4. Cells in culture normally produce CO2 that easily combines with water forming 
carbonic acid (H2CO3) which in turn rapidly dissociates to form hydrogen ions (H
+) and 
bicarbonate (HCO3
-) leading to a decrease of medium pH and consequent inhibition of cell 
growth. 
 Phenol red is another component of RPMI 1640 medium; it is pH indicator able to 
provide gross information on cell metabolism: in acidic environment its colour turns from 
the medium purple to yellow. FBS is added to RPMI 1640 medium as a source of growth 
factors as well as L-Glutamine, an essential amino acid used for protein production, as an 
energy source, and in nucleic acid metabolism.  
 
Culture medium Components 
RPMI 1640 
Completed medium 
Sodium bicarbonate 
Phenol red 
Non-essential amino acids 
L- Glutamine 2 mM 
FBS 15% (v/v) heat-inactivated 
Penicillin 100 U/mL 
Streptomycin 100 µg/mL 
 
Table 1. Components contained in RPMI 1640 (Sigma Aldrich) medium 
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3.1.2 . Mycoplasma detection method 
To detect the presence of mycoplasmas in the cell cultures the q-RT-PCR method was 
used [see chapter 3.5.]. To perform the q-RT-PCR sequencing primers against tuf gene 
(which encodes peptide chain elongation factor Tu) were designed. These designed primers 
match tuf gene of 19 mycoplasmas on the public database  
(5’-TCCAGGWCAYGCTGACTA-3' as a forward primer and  
5'-ATTTTWGGAACKCCWACTTG-3' as a reverse primer).  
 
The samples were prepared as follows: 
1. 2-3 × 105 cells were washed with phosphate buffer saline (PBS) 1×. 
Reagent Amount to add in 1L of distilled water Final concentration 
NaCl 8 g 137 mM 
KCl 0.2 g 2.7 mM 
Na2HPO4 1.44 g 10 mM 
KH2PO4 0.24 g 1.8 mM 
Table 2.  Recipe for preparation 1 L PBS 1× 
 
2. Cells were resuspended in 10 µL RNase free water. 
3. Samples were boiled at 95°C 15min. 
4. The thermal cycle of q-RT-PCR was set as follow: 95°C for 10 min, required to 
activate DNA polymerase followed by 95°C for 30 sec (denaturation), 60°C for 
15 sec (annealing), 72°C for 30 sec (extension). No more than 40 cycles of 
amplification were used. 
Mix Volume / µL 
MASTER MIX (10× buffer, MgCl2 25mM, dNTPs mix, 
Taq Pol 5 U/µL, Syber Green) 
12.5 
5’ primer 0.3 µM 1.5 
3’ primer 0.3 µM 1.5 
dH2O Fill to 25 
Template 1 
Table 3. Quantitative and qualitative composition of mixture for q-RT-PCR  
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3.1.3. Cells Cryopreservation and Resuscitation  
In order to prevent the risk of genetic and morphological changes, thus to reduce the 
risk of contamination and to slow down the aging process mammalian cell lines need to be 
cryopreserved.  
 
This process was performed as follows: 
1. Viable cells were counted, centrifuged at 800 rpm for 10 min and the supernatant 
was discarded 
2. Cells were resuspended in the freezing medium (see Table 4) at an optimal 
concentration of 2-10 x106 cells/mL and aliquoted in cryogenic vials 
3. Each vial was placed in ice for 30 min in order to obtain a slowly freezing and 
maintain the cell membrane integrity. Finally vials were transferred into a -80°C 
freezer. 
Component % 
FBS 90 
DMSO 10 
Table 4. Composition of cryopreservation medium 
 
Cell lines were resuscitated by rapid thawing at 37°C and DMSO dilution with 10 mL 
of warmed RPMI 1640 complete medium. Thereafter cells were centrifuged at 800 rpm for 
10 min, the supernatant was pour off and the pellet resuspended in fresh medium in a T25 
cm2 flask. 
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3.2.  CELL VIABILITY ASSAY 
Lymphoblasts were counted and split at a density of 500.000 cells/mL. To check the 
cell viability in presence and absence of DETA-NONOate at different concentrations we 
used the Trypan Blue (TB) solution method. TB is a cell impermeable molecule able to 
penetrate only into the cells with damaged membrane that become clearly recognisable at 
the optical microscope for their distinctive blue colour. 
Approximately 20 x 103 cells were seeded in each well of a 96 multiwell plate 
(CELLSTAR®) at a final concentration of 2x105 cell/mL and treated with DETA-
NONOate at concentrations ranging from 0.01 to 0.5 mM for 48 h. DETA-NONOate is a 
NO· donor with 20 h of half-life at 37°C, therefore it was added again to the cells after 24 
h of incubation. Afterwards, cells were collected and their viability was determined using 
TB. Each condition was performed in triplicate.  
Protocol for counting cells with Hemocytometer (Fig. 13) 
1. Cell sample was dilute 1:1 in a 0.4% TB solution (Sigma-Aldrich). 
2. The glass cover slip was placed over the counting chambers. 
3. 10µL of cell sample were pipetted into the hemocytometer. 
4. The hemocytometer was placed under a microscope with typical magnification of 
100×. 
5. Focus onto the grid pattern and count the number of cells in the middle square of 
the two grids. 
6. To calculate the total number of viable cells in the flask was calculated using the 
formula below: 
Total cells counted x dilution factor (2) x 10.000 cells/mL 
Number of hemocytometer squares 
 
 
 
 
 
 
 
 
Figure 13. Hemocytometer (Neubauer chamber) [from lifetechnologies.com website] 
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3.3.  PROTEIN CONTENT QUANTIFICATION 
3.3.1. Bradford assay 
The Bradford protein assay is a method commonly used to measure the concentration of 
total proteins in biological samples. The assay is based on the shift of absorbance from 465 
nm (brown) to 595 nm (blue) that occurs when proteins bind to Coomassie Brilliant Blue 
G-250 dye under acid conditions[Bradford 1976]. This method measures the presence of 
basic (e.g. arginine; lysine) and aromatic (e.g. histidine) amino acid residues that are 
primarily involved in the protein-dye complex formation (Fig. 14.). 
To perform the protein quantification assay the Bio-Rad Protein Assay Solution was 
used and the standard curve was built using 2mg/mL bovine serum albumin (BSA) as 
reference protein. Briefly, serial BSA protein dilutions were made (2; 4; 6; 8; 10µg/mL) in 
order to obtain a standard curve and 1µL of lysate was diluted in 200 µL of Bradford 
solution and brought up to 1mL using Milli-Q water. Sample and standards were incubated 
at room temperature (25 °C) for 5 min, transferred to disposable cuvette and the 
absorbance was read at 595 nm. The regression coefficient was calculated using the BSA 
standard curve. 
 
 
Figure 14. Forming of protein-Dye blue complex [from qcbio.com website] 
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3.3.2. Bicinchoninic Acid assay (BCA) 
The BCA protein assay is a colorimetric technique commonly used to detect and 
quantify the total protein concentration. The assay relies on the principle that in an alkaline 
environment Cu2+ ions are reduced to Cu+ by proteins. The bicinchoninic acid is a specific 
reagent for Cu+ ions forming with them a purple-blue complex whose colour is 
proportional to the total protein present in the sample (Fig. 15) [Walker J. M. 2002]. For 
the assay the BCA Kit (Sigma Aldrich) was used and the standard curve was built using a 
series of BSA protein dilutions. Briefly, an aliquot of 2 µL of sample and standard were 
diluted in 1 mL of BCA working reagent obtained mixing 50 parts of solution A with 1 
part of solution B. Both samples and standards were incubated at 37°C for 30 min and the 
absorbance was measured at 562 nm using a Jasco V-650 spectrophotometer. Using the 
BSA standard curve (Fig. 16) protein concentration of the samples was calculated. 
  
 
Figure 15. Reduction of Cu2+ and reaction with BCA forming purple-blue complex [from 
nfsc4500101groupa.weebly.com website]  
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Figure 16. Standard curve for BCA assay obtained using a Jasco V-650 spectrophotometer 
 
3.4. QUANTITATIVE REAL TIME POLYMERASE CHAIN 
REACTION 
The q-RT-PCR is a common method used to produce in few hours millions of copies of 
specific DNA sections and obtaining enough DNA required for further analysis. The 
method is so-called because the amplification of DNA with a PCR is monitored in real 
time (q-RT-PCR cyclers constantly scan q-RT-PCR plates). In contrast to the conventional 
PCR the q-RT-PCR is a quantitative method that enables to determine the exact 
concentration (relative or absolute) of the amplified DNA in the sample. Apart from DNA, 
also RNA can be used as a template. In this latter case the RNA needs to be purified and 
reverse transcribed into DNA (also termed complementary DNA or cDNA) before being 
amplified with q-RT-PCR. 
 
The main steps followed were: 
1. Sample preparation 
2. Retrotranscription 
3. q-RT-PCR 
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1. Sample preparation 
RNA purification 
RNA purification is the first and crucial step of q-RT-PCR and it has to be performed 
accurately in order to exclude all those factors that could negatively influence the quality 
of the analysis. Degradation of the RNA is a critical issue during sample preparation as 
well as the possible presence of organic solvents, (commonly used during the RNA 
extraction process) DNA and proteins. 
RNA purification from cultured cell lines is consisted of several steps (Fig. 17) that 
were performed using the NucleoSpin® RNA Buffer Set (Macherey-Nagel). 
 
 
Figure 17. RNA purification steps [from bioke.com website] 
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 RNA quality control 
To assess the RNA concentration and assure the sample purity two analyses were 
performed: spectrophotometer measurement and gel electrophoresis. The absorbance ratio 
measured at 260 nm and 280 nm provides information about RNA and DNA purity. In the 
presence of “pure” RNA this ratio should be 1.9-2.1. All proteins display absorption at 280 
nm, so that if protein contamination is present in the sample a decrease of the ratio is 
expected. On the contrary when phenol and/or urea are present an absorbance at 230 nm or 
270 nm is observed with consequent increase of the ratio. To measure small volumes of the 
sample, Eppendorf BioSpectrometer was used (Fig. 18). 
 
  
 
 
 
 
 
Figure 18. Eppendorf BioSpectrometer [from labwrench.com website] 
 
Gel electrophoresis is a very useful method to determine RNA degradation and it relies 
on principle that when the two ribosomal RNA (rRNA) bands are detected without 
smearing the RNA sample is considered intact. The two sharp bands seen on the gel 
correspond to 28S and 18S rRNAs, at a ratio of 2:1. 
 
2. Retro transcription 
Once the mRNA is isolated and purified it is necessary to transcribe it into the 
complementary DNA (Fig. 19) that is used as a template for the gene amplification. 
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Figure 19. Transcription and retrotranscription of expressed gene [from saylor.org website] 
 
3. q-RT-PCR 
The amount of specific DNA section is detected using the fluorescence Syber Green dye 
that fluoresces when it is bound to the double stranded PCR products. The method is based 
on the natural process of DNA replication (Fig. 20). Briefly, the reaction occurs when a 
cDNA sample, DNA polymerase, nucleotides (dNTPs), primers (Forward and Reverse) 
and other reagents (PCR Buffer and MgCl2) are added in a PCR sample tube.  
Primers are short pieces of DNA made in laboratory and custom built according to the 
specific needs. In a PCR experiment, two primers are designed so to match the DNA 
segment that needs to be amplified (Table 5). Through complementary base pairing, one 
primer attaches to the top strand at one end of your segment of interest, and the other 
primer attaches to the bottom strand at the other end. In most cases, two primers (usually 
20 nucleotides long) are able to target just one place in the entire genome. 
 
Gene Primers 
β-actin reverse 5’AGGATGGCAAGGGACTTCCTG 3' 
β-actin forward 5’AATGTGGCCGAGGACTTTGAT 3' 
iNOS  reverse 5’ CAGCAGCCGTTCCTCCTC 3' 
iNOS forward 5' CCGAGTCAGAGTCACCATCC 3' 
eNOS reverse 5' GCTCATTCTCCAGGTGCTTCAT 3' 
eNOS forward 5' GCCGTGCTGCACAGTTACC 3' 
Table 5. Nucleic base sequences of reverse and forward primers 
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DNA polymerase commonly used is derived from a strain of bacteria called Thermus 
aquaticus that live in the hot springs and can survive near boiling temperatures able 
therefore, to be active at 72°C.  
In parallel with the analysis of the samples, negative and positive controls were also 
loaded. No template control (NTC) was used as a negative control in order to check a 
possible external contamination or primer dimer formation that could increase the 
fluorescence signal. Positive control was analysed in order to check the activity and 
specificity of the primers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Quantitative real time polymerase chain reaction [from neb.com website]
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At the end of each cycle (run) the melting curve was performed to ensure a single 
amplified product for each reaction. During the melting curve analysis, all products 
generated in the PCR amplification reaction were melted at 95°C, annealed at 55°C and 
subjected to a gradual increase in temperature. The result is a plot of raw fluorescence data 
units versus temperature and each peak in the curve indicates a specific melting product. 
Ideally, a single peak is observed and the melting temperature is the same in all reactions 
where the same sample is amplified. If secondary peaks are seen it means that the required 
product is not the only one that is amplified. As an internal control gene encoding for β-
actin has been used because it is expressed constantly and at the high levels in almost every 
cell lines and they were used to normalize changes in specific gene expressions. 
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4.  RESULTS AND DISCUSSION 
4.1.  MYCOPLASMA CONTAMINATION TEST 
Mycoplasma is the most common contaminant of cell cultures with an average infection 
rate of 25% of the worldwide cell cultures [Uphoff et al 2001] and is considered a major 
problem in biological studies. This type of contamination is of particular importance since, 
contrary to bacterial infection, it can be detected only through special assays. Moreover 
mycoplasma strains are usually resistant to many of the commonly used antibiotics 
challenging the eradication. Manifestations of mycoplasma contamination are variable 
even though the most common remarkable effect is an irreversible deterioration and loss of 
cell cultures. One of the most common and reliable method to detect mycoplasma 
contaminants is the q-RT-PCR technique.  Recently, a number of q-RT-PCR assays have 
been described for a variety of mycoplasmas 
To assess the absence or presence of mycoplasma contaminations in our cell cultures, 
we performed a q-RT-PCR. We selected a couple of primers and run a q-RT-PCR on both 
controls and LHON lymphoblasts cell lines at the beginning and at the end of this thesis 
project. In order to check the specificity of our primers we also loaded a positive 
mycoplasma control. In all the q-RT-PCR we performed we did not detect any presence of 
mycoplasma contamination. 
 
4.2. CELL VIABILITY ASSAY 
In order to assess the control and LHON cell lines viability in presence of NO· we 
performed a viability assay on cells incubated with different concentration of the NO· 
releaser DETA-NONOate. Lymphoblast cells, obtained from the LHON patient and 
healthy controls (CT1 and CT2), were seeded in plates and treated with four different 
concentrations of DETA-NONOate (0.01; 0.05; 0.1; 0.5 mM) for 48 hours. DETA-
NONOate is one of the most commonly used NO donors and it is suitable for long term 
incubation since it has a half-life of 20 h at 37°C allowing to maintain stable NO levels for 
a prolonged period of time. Moreover the DETA-NONOate spontaneous decomposition is 
not affected by the presence of light, metals, thiols or cells and produces only NO and 
non-toxic diethylenetriamine (DETA). 
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Since DETA-NONOate dissociation is strictly pH dependent being almost instantaneous 
at pH 5, in order to prevent accidentally NO· releasing, the DETA-NONOate stock 
solution was prepared in 0.01 NaOH and stored at -20 °C. The DETA-NONOate stock was 
thereafter diluted in RPMI-1640 immediately before addition to the cells. In order to 
guarantee a 48 h incubation the compound was added again after 24 h. At the end of the 
overall incubation time cells were collected and their viability was determined by the 
Trypan blue exclusion method; data were estimated from three independent experiments 
performed in triplicate and statistically analyzed. The results indicate that, compared to 
healthy controls, LHON patient cells are more susceptible to NO· toxicity. Particularly, 
LHON cells show a greater percentage of mortality when exposed to the higher 
concentrations of DETA-NONOate (0.05, 0.1 and 0.5 µg/mL) compared to controls ones. 
  
 
 
Figure 21. Cell viability of DETA-NONOate treated cells reported as percentage in the 
absence of the NO· releaser Controls (CTR) viability is expressed as the average of CT1 
and CT2 measurements.  
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4.3. EXPRESSION OF NOSs mRNA LEVELS 
To determinate whether NOSs mRNA levels differed between controls and LHON 
cells, we performed a q-RT-PCR analysis for the eNOS and iNOS expression genes. To 
perform this measurement, the total RNA was first extracted from the cells and its quality 
thereafter tested the quality of RNA.  
The absorption of the isolated RNAs derived both from controls (CT1 and CT2) and the 
LHON patient has been evaluated spectroscopically at 260 nm and 280 nm and the 
260/280 nm ratio, indicative of RNA purity, calculated. The results reported in Table 6 
show that the RNA extraction was successfully performed. The values of the 260/280 nm 
ratio were in between 1.9 and 2.1 indicating that as purified the RNA was free from 
contaminations by organic chemicals and proteins (see chapter 3.4., Methods and 
Materials). Moreover, using the Lambert-Beer law we were able to calculate the RNA 
concentration of samples. 
 
Sample A260nm/A280nm 
CT1 2.1 
CT2 2.1 
LHON 2.0 
Table 6. Typical A260nm/A280nm values obtained with Eppendorf BioSpectrometer® 
 
Once checked the purity of the RNA samples we further proceeded with quality 
controls: the gel electrophoresis, a method commonly used to detect the presence of 
denatured RNA. High quality and non-degraded RNA is fundamental for a good cDNA 
synthesis and down streaming q-RT-PCR steps. One of the major concerns of RNA 
extraction is the presence of ribonucleases (RNAses). These are ubiquitous enzymes 
present within the cells and tissues able to rapidly degrade the total RNA. Additionally, 
RNAses are present in various biological fluids (e.g. tears, saliva) and are particularly 
resistant to several chemical agents. For these reasons samples were prepared in the 
presence of RNAses inhibitors. 
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A picture of a typical electrophoresis gel is shown in Fig. 22. The control samples were 
overloaded so the first two bands are lighter but no smearing was present and two sharp 
bands, corresponding to 28S and 18S RNA, can be detected as expected for intact RNA 
samples. 
 
 
Figure 22. Picture of electrophoresis gel taken with ChemiDoc MP System (BioRad) 
 
After having assessed the good quality of the RNA samples, the q-RT-PCR analysis 
was performed. The amount of amplified DNA coding either for iNOS or for eNOS was 
detected using the fluorescence Syber Green dye that fluoresces when it is bound to the 
double stranded PCR products. The results were analysed using ddCt method, which 
comprises the 2-ΔΔCT.  This is a convenient method for acquiring relative expression of the 
target gene in different samples. It requires the assignment of one or more housekeeping 
genes, which are assumed to be uniformly and constantly expressed in all samples. The 
analysis shown in Fig. 23 and Fig. 24, although apparently suggestive of different 
expression of the iNOS and eNOS mRNA in LHON and control cells was not statistically 
different. At this stage the conclusion can only be that more experiments are necessary to 
assess possible differences between LHON and control cells in the expression and activity 
of these enzymes. 
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Figure 23. Relative expression of amplified DNA coding for iNOS in controls and LHON 
cells 
 
Figure 24. Relative expression of amplified DNA coding for eNOS in controls and LHON 
cells 
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5.  CONCLUSION  
In this thesis work, we investigated the potential role of NO· in the LHON development 
and progression. The alteration of mitochondrial respiratory chain function with 
consequent deficit in ATP levels and increased ROS production are two of the main 
biochemical features of the LHON pathology leading to the preferential loss of RGCs and 
subsequent optic nerve degeneration. Although several studies carried on cell and animal 
models unravelled some of the molecular and biochemical bases underlying the LHON 
pathology, many open questions still persist making difficult to provide an efficient 
therapy able to prevent and reverse the LHON symptoms.  
NO· is an established modulator of mitochondrial function, we have therefore addressed 
the question whether changes in the NO· metabolism could have a role in the LHON 
pathophysiology. With this aim in mind, we analysed the viability of LHON cells cultured 
in the presence of the NO· releaser DETA-NONOate, mimicking a chronic increase of 
NO· bioavailability, as it might occur in vivo particularly due to iNOS activation. The 
assay revealed that NO· has a greater impact on LHON cell viability whereas control 
lymphoblasts were able to cope much better with nitrosative stress. 
 These data suggest that in LHON cells the exposure to high NO· levels leading to 
overproduction of reactive oxygen and nitrogen species (RONS), impairs the redox 
homeostasis, exacerbates mitochondrial dysfunction, thereby leading to cell death.  
Finally, we checked the mRNA NOSs level to verify whether in the absence of 
exogenous NO·, LHON cells undergo nitrosative stress as a consequence of an increased 
nitric oxide synthases expression (and activity). At this stage, our data show similar eNOS 
and iNOS mRNA expression in LHON and control cells. As already mentioned, more 
experiments are necessary, even though we cannot exclude that the intrinsic enzymatic 
activity could be different in controls and LHON patients. 
The future perspective will be to investigate more deeply the role of nitric oxide in the 
LHON pathophysiology, in order to assess if this small gas molecule could affect the 
OXPHOS ATP production and cell bioenergetics. If the ongoing experiments will confirm 
the preliminary observations, then it is tempting to speculate that the lower levels of NOSs 
found in LHON patients may represent a cell attempt to inhibit NO synthesis, thus 
lowering peroxynitrite. Indeed, a better knowledge of the molecular mechanisms of LHON 
disorder would lead to the development of efficient therapies.  
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7. SUMMARY 
Due to complex interactions of mitochondrial and nuclear DNA, the real cause of 
inherited mitochondrial diseases is still unclear and patients currently lack effective 
treatments. Leber’s hereditary optic neuropathy, one of the most common inherited optic 
neuropathies, is caused by point mutations in mtDNA that result in a defect of respiratory 
chain complex I activity.   
From the biochemical point of view the bioenergetic failure and the enhanced reactive 
oxygen species (ROS) production are typical hallmarks of LHON disease, but still they do 
not explain the late onset and the incomplete penetrance. Moreover it is still unknown why, 
although the mutation is present overall the body only the RGCs are affected. Since LHON 
is characterized by a deficit in the oxidative phosphorylation chain and NO· is an 
established mitochondrial respiratory chain negative modulator, we checked if it might 
have a role in the LHON development and progression. 
The results presented in this thesis prove that long–term exposure to NO· has a larger 
impact on LHON cells viability compared to controls  and suggest that higher levels of 
reactive oxygen and nitrogen species (ONOO-) are produced in this pathological state, 
leading to cell death.  In addition, careful though still statistically insufficient evaluations  
of the levels of iNOS and eNOS mRNA expression seems to suggest that there might be a 
difference in the expression of one or more NOSs in LHON patients: this question however 
remains open. Future perspectives are, indeed, to provide a complete picture about 
involvement of NO in this specific mitochondrial disease and to solve the conundrum of 
the NOSs expression and activity. . The feeling is that the NO· metabolism can be relevant 
to LHON pathophysiology, its comprehension opening to the development of more 
efficient therapeutic and preventive interventions.  
  
 
PROŠIRENI SAŽETAK 
UVOD 
Dušikov oksid (NO·) jednostavan je plin koji u animalnoj fiziologiji ima važnu ulogu 
kao signalna molekula u procesima koji reguliraju cirkulaciju krvi, aktivaciju imunosnog 
sustava, prijenos živčanih signala kao i u procesima koji moduliraju mitohondrijsku 
respiraciju. NO· također ima ulogu u razvoju nekih bolesti no točni mehanizmi još uvijek 
nisu poznati. U eukariotskim stanicama sinteza NO· katalizirana je članovima porodice 
enzima koja je nazvana sintaze dušikovog oksida (NOSs). 
Mitohondrij je stanični organel koji sadrži vlastitu kužnu DNA i odgovoran je za 
produkciju najveće količine energije u stanici u procesu oksidativne fosforilacije. 
Mitohondrijski genom se nalazi u neposrednoj blizini sustava oksidativne fosforilacije koji 
je veliki izvor reaktivnih oksidativnih spojeva pa je, prema tome, izloženiji mutacijskim 
promjenama od nuklearnog genoma što može dovesti do razvoja bolesti. Složene 
interakcije mitohondrijske i nuklearne DNA onemogućuju otkrivanje pravog uzroka 
nasljednih mitohondrijskih bolesti kao i pružanje  učinkovite terapije. 
Leberova nasljedna optička neuropatija (LHON), jedna od najučestalijih nasljednih 
optičkih neuropatija, posljedica je točkastih mutacija mitohondrijske DNA koje dovode do 
smanjenja aktivnosti kompleksa I u respiratornom lancu. Tipična su obilježja LHON-a, sa 
biokemijskog stajališta, smanjenje proizvodnje energije na staničnoj razini i povećana 
proizvodnja reaktivnih kisikovih (ROS) i dušikovih (RONS) spojeva no to ne objašnjava 
odgođenu pojavu simptoma bolesti i učinak samo na određene stanice. Naime, premda je 
mutacija prisutna u cijelom tijelu, štetan se učinak očituje samo na ganglijskim stanicama 
mrežnice. Obzirom da je LHON karakteriziran deficitom oksidativne fosforilacije, a NO· 
je poznati negativni modulator mitohondrijskog respiratornog lanca istražili smo njegovu 
ulogu u razvoju LHON-a. 
  
 
 MATERIJALI I METODE 
Nakon uzgoja staničnih kultura ljudskih limfoblasta, uzetih od pacijenta nositelja 
mutacije odgovorne za nastanak LHONA i zdravih kontrolnih stanica, mogli smo 
proučavati utjecaj NO· na smrtnost stanica.  Stanične kulture su uzgajane u propisanom 
mediju (RPMI 1640) pod standardnim uvjetima. Imajući na umu opasnost od zaraze 
staničnih kultura mikoplazmama, provjerili smo njihovu prisutnost pomoću q-RT-PCR 
koristeći 5’-TCCAGGWCAYGCTGACTA-3' i 5'-ATTTTWGGAACKCCWACTTG-3' 
kao početnice. Analizu smo proveli na početku i na kraju istraživanja za ovaj rad te smo 
ustvrdili da kulture stanica nisu zaražene sa mikoplazmama.  
U svrhu proučavanja utjecaja NO· na smrtnost stanica poslužili smo se s DETA 
NONOate kao stalnim donorom NO·. Stanice limfoblasta uzete od pacijenta nositelja 
mutacije A11778G koji boluje od Leberove nasljedne optičke neuropatije i od zdravih 
pojedinaca istog spola raspodijeljene su na ploči sa 96 jažica. 20 x 103 stanica je stavljeno 
u pojedinu jažicu i to tako da konačna koncentracija bude 2x105 stanica/mL. Tretirane su 
sa DETA-NONOate u rangu koncentracija od 0,01 do 0,5 mM u periodu od 48 sati. Nakon 
završenog perioda, žive stanice su brojane uz pomoć hemocitometra dodatkom Trypan 
Blue otopine. 
Količina iNOS-a i eNOS-a na razini mRNA provjerena je metodom kvantitativne 
polimerazne lančane reakcije u stvarnom vremenu. Pročišćavanje RNA provedeno je uz 
pomoć NucleoSpin® RNA Buffer Set (Macherey-Nagel) prema standardnom postupku a 
kvaliteta je provjerena spektrofotometrijski pomoću Eppendorf BioSpectrometer i 
provođenjem gel elektroforeze. Nakon retrotranskripcije mRNA u Cdna izveli smo q-RT-
PCR koristeći početnice za β-aktin, iNOS I eNOS. β-aktin služi za normalizaciju rezultata 
koja je potrebna pri korištenju ddCt metode kojom smo analizirali podatke.  
  
 
REZULTATI I RASPRAVA 
Rezultati su pokazali da dugotrajna izloženost dušikovom oksidu ima veći utjecaj na 
smrtnost stanica LHON-a uspoređujući je sa smrtnosti kontrolnih stanica i pretpostavljaju 
da se ROS i RONS stvaraju u većim količinama u ovom patološkom stanju i vode ka 
staničnoj smrti. 
U pripremi q-RT-PCR, pročišćena mRNA je bila prikladna za analizu jer je 
spektrofotometrijski određen omjer vrijednosti izmjeren na 260 nm i 280 nm u svim 
slučajevima bio između 1,9 i 2,1. Nadalje, gel elektroforezom smo jasno vidjeli 2 oštre 
linije koje ukazuju na konzistentnost pročišćene mRNA. Provedenom q-RT-PCR analizom 
dobili smo rezultate koji, iako nisu statistički značajni, pretpostavljaju da postoji razlika u 
ekspresiji jednog ili više NOS enzima kod pacijenata oboljelih od LHON-a, ali ovo pitanje 
ostaje otvoreno za daljnja istraživanja. 
Buduća je perspektiva potpuno objašnjenje uloge NO· u specifičnim mitohondrijskim 
bolestima i rješavanje zagonetne ekspresije i aktivnosti samog NOS-a. Možda upravo 
metabolizam NO· može biti važan u patofiziologiji LHON-a te njegovo razumijevanje 
može pridonijeti razvoju efikasnijih terapija i preventivnih mjera. 
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SUMMARY 
 
Due to complex interactions of mitochondrial and nuclear DNA, the real cause of inherited mitochondrial 
diseases is still unclear and patients currently lack effective treatments. Leber’s hereditary optic neuropathy 
(LHON), one of the most common inherited optic neuropathies, is caused by point mutations in mtDNA 
that result in a defect of respiratory chain complex I activity.  From the biochemical point of view the 
bioenergetic failure and the enhanced reactive oxygen species (ROS) production are typical hallmarks of 
LHON disease, but still they do not explain the late onset and the incomplete penetrance. Moreover it is still 
unknown why, although the mutation is present overall the body only the RGCs are affected. Since LHON 
is characterized by a deficit in the oxidative phosphorylation chain and NO· is an established mitochondrial 
respiratory chain negative modulator, we checked if it might have a role in the LHON development and 
progression. The results presented in this thesis prove that long–term exposure to NO· has a larger impact 
on LHON cells viability compared to controls  and suggest that higher levels of reactive oxygen and 
nitrogen species (ONOO-) are produced in this pathological state, leading to cell death.  In addition, careful 
though still statistically insufficient evaluations  of the levels of iNOS and eNOS mRNA expression seems 
to suggest that there might be a difference in the expression of one or more NOSs in LHON patients: this 
question however remains open. Future perspectives are, indeed, to provide a complete picture about 
involvement of NO· in this specific mitochondrial disease and to solve the conundrum of the NOSs 
expression and activity. . The feeling is that the NO· metabolism can be relevant to LHON 
pathophysiology, its comprehension opening to the development of more efficient therapeutic and 
preventive interventions. 
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